

1. **[AYUSH-US Pharmacopeial Convention MoU on traditional medicines](#) – Business Standard**

The AYUSH Ministry today signed an agreement with United States Pharmacopeial Convention (USP) for cooperation in the field of traditional medicines, a move which will also help improve these medicines' quality. The Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H) under the Ministry signed the MoU with USP which aims at collaborating, identifying, and development and dissemination

of science-based standards in this field. "The aim of this historic MoU is to promote the safety, quality and integrity of traditional medicines and botanical dietary supplements," an official statement said.

1. [AYUSH-US Pharmacopeial Convention MoU on traditional medicines](#) – Business Standard
2. ['Quality health care must for India'](#) – Business Standard
3. [Pharmacies show restraint in selling anti-TB drugs: Study](#) – The Hindu
4. [Global medical tourism meet in Hyderabad](#) – The Hans India
5. [US patent office rules in favour of Natco Pharma's US partner Mylan](#) – Mint
6. [Natco Pharma gets favourable EIR report for Chennai facility](#) – The Hindu Business Line
7. [CPhI Pre-Connect Congress outlines current trends in Pharma](#) – Pharmabiz.com

2. **['Quality health care must for India'](#) – Business Standard**

Emphasising that India needs to transform its healthcare sector as it loses huge amount of money due to premature deaths and preventable illnesses every year, experts say that providing access to quality healthcare for 1.25 crore people was a huge challenge that the country must meet.

"We house 16 per cent of world's population and 21 per cent of world's disease burden equalling loss of 6 per cent of India's GDP due to premature deaths and preventable illnesses. It is estimated that the increasing Non-Communicable Disease (NCD) burden will cost India \$4.58 trillion due to loss of productivity," said Nandakumar Jairam, chairman, Ficci Health Services Committee, according to a release.

Similar report-

- [FICCI welcomes Department of Pharmaceutical's move towards broadbased stakeholder consultations](#) – Business Standard

3. **[Pharmacies show restraint in selling anti-TB drugs: Study](#) – The Hindu**

For a country that consumes the most antibiotics in the world, a pattern largely fuelled by the ready availability of even prescription drugs over the counter, Indian pharmacies have shown restraint in dispensing anti-tuberculosis drugs, a new study has found. However, drugs that can delay tuberculosis diagnosis are still available over the counter.

The study published in journal Lancet states that none of the pharmacies mapped in Mumbai, Delhi and Patna dispensed first-line anti-tuberculosis drugs, and the use of stronger fluoroquinolone antibiotics and heavily-restricted drug classes was low. The study says: "Furthermore, the use of all antibiotics decreased sharply when the patient's diagnosis was made available to the pharmacists."

Also reported by-

- [Million India TB patients missing from statistics, say study](#) – Mint
- [Overuse of antibiotics harming India's fight against TB: Lancet](#) – Business Standard
- [Private hospitals must report TB cases to government, say officials](#) – Hindustan Times

4. [Global medical tourism meet in Hyderabad](#) – The Hans India

Medical tourism industry experts and other related professionals from over 50 countries are expected to take part in the third edition of International India Medical Tourism Congress (IIMTC 2016) which will be held on the city outskirts on September 3-4. Supported by the Ministry of Tourism and Culture, Telangana, this two-day event is aimed at making India a preferred global medical tourism hub. It will also support the medical tourism stakeholders in India and other parts of the world.

5. [US patent office rules in favour of Natco Pharma's US partner Mylan](#) – Mint

Drugmaker Natco Pharma Ltd on Thursday said the US Patent and Trademark Office (PTO) has ruled in favour of its partner Mylan NV by striking down two patents held by Israel-based Teva Pharmaceutical Industries Ltd for its blockbuster drug Copaxone 40 mg/mL formulation. "The US PTO has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of two related Copaxone 40 mg patents to be unpatentable," Natco said in a statement.

Generically called glatiramer acetate injection, Copaxone is an injectable drug to treat relapsing forms of multiple sclerosis which damages the central nervous system and affects some 400,000 Americans.

Also reported by-

- [Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents](#) – Business Standard
- [U.S. patent office rules in favour of Mylan](#) – The Hindu

6. [Natco Pharma gets favourable EIR report for Chennai facility](#) – The Hindu Business Line

Natco Pharma Ltd has announced that it has received a successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its chemical division in Chennai, named Natco Organics Ltd, prior to amalgamation into the company. The FDA inspection was conducted during February 8-12, according to a regulatory statement filed with the BSE.

Also reported by-

- [Natco Pharma zooms on EIR for Chennai facility](#) – Business Standard

7. [CPhI Pre-Connect Congress outlines current trends in Pharma](#) – Pharmabiz.com

CPhI Worldwide, organized by UBM EMEA, has announced the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3. The platform brings together experts and thought leaders from the entire pharmaceutical industry to provide insights on the major developments in the industry, with innovation, contract services and patient centricity taking centre stage this year. Providing six tracks across three different theatres throughout the day, delivered by more than 40 senior level speakers, the Pre-Connect Congress will cover the full spectrum of the pharma value chain; across 'contract services', 'drug design and delivery', 'pharma ingredients', 'biologics and biosimilars', 'finished dosages and generics' and 'pharma packaging'. Over 250 attendees from more than 68 different organisations – spanning an enormous 32 countries – are expected to gather at Conference Centre 1, Fira de Barcelona Gran Via, Barcelona – Spain.